

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Cardiomyopathy associated with muscular dystrophy	CUG triplet repeat, RNA binding protein 1 (CUGBP1); protein kinase C (PKC)	<p>Studies in mice suggest that inhibiting PKC could help treat cardiomyopathy associated with myotonic dystrophy type 1 (DM1). In a mouse model of cardiac-specific DM1, a PKC inhibitor decreased CUGBP1 levels and cardiac structural defects and increased survival compared with saline. Next steps could include testing chronic administration of the inhibitors.</p> <p>At least four companies have PKC inhibitors in clinical testing for various indications.</p> <p>SciBX 2(46); doi:10.1038/scibx.2009.1691 Published online Dec. 3, 2009</p>	Patent and licensing status unavailable	<p>Wang, G. <i>et al. J. Clin. Invest.</i>; published online Nov. 9, 2009; doi:10.1172/JCI37976</p> <p>Contact: Thomas A. Cooper, Baylor College of Medicine, Houston, Texas e-mail: tcooper@bcm.edu</p>